Electrocore yesterday registered for an initial public offering worth nearly $75 million, detailing plans to expand its GammaCore device beyond the two headache treatments it’s already cleared for in the U.S. The Basking Ridge, N.J.-based company said in a regulatory filing that it plans to use the $74.8 million IPO’s net proceeds to expand its sales […]
DHS warns of cybersecurity weakness in Medtronic N’Vision neurostim programmer
The Department of Homeland Security this week released a report warning of cybersecurity vulnerabilities in Medtronic‘s (NYSE:MDT) N’Vision clinician programmer designed for use with neurostimulation devices that could allow outside agents to access personal health data. The DHS said that the vulnerability was originally reported by Whitescope LLC, and requires an individual gain physical access to […]
StimGuard wins CE Mark for SNS overactive bladder treatment
StimGuard said today it won CE Mark approval in the European Union for its sacral nerve stimulator designed to treat intractable symptoms of overactive bladder, with plans to launch the device in the EU this summer. The Pompany Beach, Fla.-based company touted that the StimGuard SNS system can be implanted through a needle without a surgery, […]
Nexstim launches NBT major depressive disorder TMS treatment device in US
Nexstim said today it launched its Navigated Brain Therapy transcranial magnetic stimulation system designed to treat major depressive disorder in the US, having won FDA approval for the device last November. The Helsinki-based company announced the launch at the Clinical TMS Society’s annual meeting in New York. “We are extremely pleased to announce the launch of […]
Judge sanctions Boston Scientific lawyers in Nevro patent row
A federal judge in California yesterday sanction lawyers for Boston Scientific (NYSE:BSX) in a patent infringement battle with neurostimulation rival Nevro (NYSE:NVRO). Back in October 2017, Judge Vince Chhabria of the U.S. District Court for Norther California found that, although the Nevro attorneys’ failure to correct a patent examiner’s misunderstanding of prior art was a little “sleazy,” it didn’t amount […]
Nevro dives on missed Q1 estimates
Share in Nevro Corp. (NYSE:NVRO) took a hit on Wall Street today as investors reacted to first-quarter sales and earnings numbers that missed the forecast. The Redwood City, Calif.-based neuromodulation company yesterday posted losses of -$17.5 million, or -59¢ per share, on sales of $87.6 million for the three months ended March 31, increasing its losses […]
Inspire Medical prices up-sized $108m IPO
Inspire Medical Systems yesterday up-sized its initial public offering to $108 million, or some $124 million if the underwriters option is exercised in full. Maple Grove, Minn.-based Inspire, which spun out from Medtronic (NYSE:MDT) in 2007, makes devices for treating obstructive sleep apnea. The company had said it planned to issue 5 million shares at $14 to $16 apiece, […]
Medtronic wins FDA PMA for DBS epilepsy treatment
Medtronic (NYSE:MDT) said today it won FDA premarket approval for its Deep Brain Stimulation therapy, indicated as an adjunctive treatment for reducing the frequency of partial-onset seizures. The DBS treatment is cleared for patients 18 years or older who are refractory or drug resistant to three or more antiepileptic medications, the Fridley, Minn.-based company said. Medtronic’s […]
Cardio neuromod group Cardionomic raises $9m
Cardionomic has raised $9 million in a new round of equity financing, according to an SEC filing posted this week. The company is developing a neuromodulation therapy device to treat acute decompensated heart failure, a condition in which fluid accumulates in the lungs and other tissues in patients with heart failure. Money in the round […]
The 10 hottest medtech startups of 2018
There’s a complaint sometimes that innovation is too incremental in the medical device industry. But don’t tell that to the people running the 10 companies included in Medical Design & Outsourcing and MassDevice’s list of the hottest medtech startups of 2018. Our editors came up with a list of 20 interesting young companies. We then […]
Boston Scientific touts 1-year data on Vercise DBS in Parkinson’s
Boston Scientific (NYSE:BSX) today released one-year data from a study of its Vercise deep-brain stimulation device in treating Parkinson’s disease. Vercise, which is based on cochlear implant technology, is designed to stimulate a targeted region of the brain via independently controlled leads. The 292-patient Intrepid trial of subjects with advanced, levodopa-responsive Parkinson’s is a double-blind, sham-controlled study with a […]
- 1
- 2
- 3
- …
- 45
- Next Page »
MassDevice Network
@MassDevice
LinkedIn
Google+